From my perspective, the most important outcome is not whether one compound is added to a list
Bn cn ung nc b in gii trong cc trng hp sau: Vn ng mnh, tp th dc cng cao Hc tp v lm vic lin tc trong mi trng nng bc gy nhiu m hi Nn ma nhiu Tiu chy nng Nghin ru B tiu ng khin i tiu nhiu Ri lon n ung B vt bng nng Mt cn bng in gii s khin bn b au u, chng mt, suy nhc c th, chut rt, co tht c, hn m, tn thng no hay thm ch l t vong
By transiently enhancing microvascular perfusion and tissue permeability, LIST establishes an optimized biologic window for the targeted intralesional delivery applied in Phase 3
It is not always possible to determine if the adverse event directly resulted from use of the drug or if other factors may have contributed to these adverse events
Native, intact glucagon-like peptide 1 is a natural suppressor of thrombus growth under physiological flow conditions